MRNS stock is down on clinical trial data Marinus Pharmaceuticals (NASDAQ:MRNS) stock is taking a beating on Monday after the pharmaceutical company announced results from a Phase 3 clinical trial. It’s bad news for MRNS stockholders today as the Phase 3 trial of intravenous ganaxolone as a…
#mrns #rse #scottbraunstein #soligenix #hawaiianelectric #buyinformatica #williamwhite
Continue reading...